BRIEF published on 09/17/2025 at 07:35, 2 months 17 days ago Sensorion announces its 2025 half-year results Funding Gene Therapy SENS-401 SENS-501 2025 Results
PRESS RELEASE published on 09/17/2025 at 07:30, 2 months 17 days ago Inside Information / News release on accounts, results Sensorion reports 2025 half-year results, corporate update, and availability of half-year report. Progress in gene therapy programs for hearing loss disorders discussed Clinical Trials Gene Therapy Sensorion Hearing Loss Disorders 2025 Half-Year Results
BRIEF published on 09/04/2025 at 07:35, 3 months ago Sensorion to Present at 60th Inner Ear Biology Workshop Biotechnology Gene Therapy Sensorion Hearing Loss Inner Ear Biology Workshop
PRESS RELEASE published on 09/04/2025 at 07:30, 3 months ago Inside Information / Other news releases Sensorion announces participation in the 60th Annual Inner Ear Biology Workshop presenting gene therapy research for hearing loss disorders Research Gene Therapy Sensorion Hearing Loss Disorders Inner Ear Biology Workshop
BRIEF published on 08/15/2025 at 07:35, 3 months 20 days ago Sensorion Strengthens its Liquidity Contract with Kepler Cheuvreux Liquidity Biotechnology Euronext Kepler Cheuvreux Sensorion
PRESS RELEASE published on 08/15/2025 at 07:30, 3 months 20 days ago Inside Information / Other news releases Sensorion increases resources allocated to liquidity contract with Kepler Cheuvreux by €60,000 to enhance liquidity of shares on Euronext Paris. The move is in accordance with AMF Decision No. 2021-01 Euronext Paris Liquidity Contract Kepler Cheuvreux AMF Decision Sensorion
BRIEF published on 07/31/2025 at 09:22, 4 months 4 days ago Sensorion Announces Participation in Investor Conferences Biotechnology Investor Conferences Sensorion Hearing Therapies September-October 2025
BRIEF published on 07/01/2025 at 07:35, 5 months 3 days ago Sensorion Reports Positive Preliminary Data from Audiogene Phase 1/2 Trial Gene Therapy Sensorion SENS-501 Congenital Deafness Audiogene Trial
PRESS RELEASE published on 07/01/2025 at 07:30, 5 months 3 days ago Inside Information / Other news releases Sensorion announces positive data from the first cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial, showing safety and hearing improvement in toddlers. Second cohort recruitment near completion Gene Therapy Clinical Trial Sensorion Audiogene Hearing Improvement
BRIEF published on 05/13/2025 at 07:35, 6 months 22 days ago Sensorion Announces Approval of Shareholders’ Meeting Resolutions Biotechnology Gene Therapy Shareholder Resolutions Sensorion Hearing Loss Therapy
Published on 12/05/2025 at 02:35, 1 hour 54 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 3 hours 29 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 5 hours 24 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 5 hours 29 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 59 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 4 hours 38 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 4 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 8 hours 14 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 9 hours 19 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 10 hours 29 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 10 hours 44 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 10 hours 45 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 21 hours 28 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 10 hours ago Declaration of voting rights at the end of November 2025
